litlas
Log inCreate account

John M. Pagel

Active 1994–2025

102
Papers
20,075
Citations
57
h-index
100
i10-index

Citations

Citations per year for John M. Pagel1994: 15 citations1995: 25 citations1996: 25 citations1997: 30 citations1998: 39 citations1999: 35 citations2000: 22 citations2001: 34 citations2002: 14 citations2003: 15 citations2004: 4 citations2005: 8 citations2006: 11 citations2007: 15 citations2008: 18 citations2009: 24 citations2010: 41 citations2011: 39 citations2012: 35 citations2013: 64 citations2014: 77 citations2015: 135 citations2016: 173 citations2017: 203 citations2018: 236 citations2019: 601 citations2020: 825 citations2021: 1,123 citations2022: 1,004 citations2023: 733 citations2024: 1,165 citations2025: 519 citations2026: 6 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,790 citing papers, 29.5% of this breakdownChina: 692 citing papers, 7.3% of this breakdownGermany: 647 citing papers, 6.9% of this breakdownUnited Kingdom: 614 citing papers, 6.5% of this breakdownItaly: 521 citing papers, 5.5% of this breakdownFrance: 412 citing papers, 4.4% of this breakdownAustralia: 395 citing papers, 4.2% of this breakdownSpain: 330 citing papers, 3.5% of this breakdownNetherlands: 263 citing papers, 2.8% of this breakdownCanada: 252 citing papers, 2.7% of this breakdownSwitzerland: 198 citing papers, 2.1% of this breakdownSweden: 174 citing papers, 1.8% of this breakdown
0%29.5%Other 22.8%

Institutions

Fields

  • Medicine80.5%
  • Biochemistry, Genetics and Molecular Biology14.4%
  • Immunology and Microbiology2.8%
  • Chemistry0.4%
  • Engineering0.4%
  • Computer Science0.3%
  • Other1.2%

Topics

  • CAR-T cell therapy research12.8%
  • Chronic Lymphocytic Leukemia Research10.1%
  • Lymphoma Diagnosis and Treatment8.7%
  • Acute Myeloid Leukemia Research3.7%
  • Immune Cell Function and Interaction3%
  • Virus-based gene therapy research2.9%
  • Other58.8%

Coauthors

All papers

Open in search
  1. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

    Authors: Frederick L. Locke, David B. Miklos, Caron A. Jacobson, Miguel‐Angel Perales, Marie José Kersten, Olalekan O. Oluwole, Armin Ghobadi, Aaron P. Rapoport, Joseph P. McGuirk, John M. Pagel, Javier Muñoz, Umar Farooq, Tom van Meerten, Patrick M. Reagan, Anna Sureda, Ian W. Flinn, Peter Vandenberghe, Kevin Song, Michael Dickinson, Monique C. Minnema, Peter A. Riedell, Lori A. Leslie, Sridhar Chaganti, Yin Yang, Simone Filosto, Jina Shah, Marco Schupp, Christina To, Paul Cheng, Leo I. Gordon, Jason R. Westin - New England Journal of Medicine 2021 cited by 1,520

  2. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

    Authors: Michael Wang, Javier Muñoz, André Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Nöel Milpied, Henry C. Fung, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Lianqing Zheng, John M. Rossi, Rajul K. Jain, Arati V. Rao, Patrick M. Reagan - New England Journal of Medicine 2020 cited by 1,823

  3. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

    Authors: Andrew W. Roberts, Matthew S. Davids, John M. Pagel, Brad S. Kahl, Soham D. Puvvada, John F. Gerecitano, Thomas J. Kipps, Mary Ann Anderson, Jennifer R. Brown, Lori A. Gressick, Shekman Wong, Martin Dunbar, Ming Zhu, Monali Desai, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, William G. Wierda, John F. Seymour - New England Journal of Medicine 2015 cited by 1,884

  4. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

    Authors: Michael Wang, Javier Muñoz, André Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Krimo Bouabdallah, Rashmi Khanal, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Patrick M. Reagan - Journal of Clinical Oncology 2022 cited by 318

  5. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

    Authors: Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutré, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Gilles Salles, William G. Wierda, Raquel Izumi, Veerendra Munugalavadla, Priti Patel, Min Hui Wang, Sofia Wong, John C. Byrd - The Lancet 2020 cited by 612

  6. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

    Authors: Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, Chan Y. Cheah, John M. Pagel, Jennifer A. Woyach, Bita Fakhri, Toby A. Eyre, Nicole Lamanna, Manish R. Patel, Alvaro J. Alencar, Ewa Lech‐Marańda, William G. Wierda, Catherine C. Coombs, James N. Gerson, Paolo Ghia, Steven Le Gouill, David Lewis, Suchitra Sundaram, Jonathon B. Cohen, Ian W. Flinn, Constantine S. Tam, Minal Barve, Bryone J. Kuss, Justin Taylor, Omar Abdel‐Wahab, Stephen J. Schuster, M. Lia Palomba, Katharine L. Lewis, Lindsey E. Roeker, Matthew S. Davids, Xuan Tan, Timothy S. Fenske, Johan Wallin, Donald E. Tsai, Nora Ku, Edward Y. Zhu, Jessica Chen, Ming Yin, Binoj C. Nair, Kevin Ebata, Narasimha Marella, Jennifer R. Brown, Michael Wang - The Lancet 2021 cited by 454

  7. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

    Authors: Bijal Shah, Michael R. Bishop, Olalekan O. Oluwole, Aaron C. Logan, Maria R. Baer, William B. Donnellan, Kristen M. O’Dwyer, Houston Holmes, Martha Arellano, Armin Ghobadi, John M. Pagel, Yi Lin, Ryan D. Cassaday, Jae H. Park, Mehrdad Abedi, Januario E. Castro, Daniel J. DeAngelo, Adriana K. Malone, Raya Mawad, Gary J. Schiller, John M. Rossi, Adrian Bot, Tong Shen, Lovely Goyal, Rajul K. Jain, Remus Vezan, William G. Wierda - Blood 2021 cited by 200

  8. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

    Authors: Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutré, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Emmanuelle Ferrant, William G. Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, John C. Byrd - Leukemia 2022 cited by 200

  9. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

    Authors: William G. Wierda, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Stephen Opat, Alessandra Tedeschi, Xavier C. Badoux, Bryone J. Kuss, Sharon Jackson, Carol Moreno, Ryan Jacobs, John M. Pagel, Ian W. Flinn, Yvonne Pak, Cathy Zhou, Edith Szafer‐Glusman, Joi Ninomoto, James P. Dean, Danelle F. James, Paolo Ghia, Constantine S. Tam - Journal of Clinical Oncology 2021 cited by 229

  10. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

    Authors: Richard R. Furman, Jeff P. Sharman, Steven Coutré, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M. Johnson, Langdon L. Miller, Daniel Li, Thomas M. Jahn, Roger Dansey, Michael Hallek, Susan O’Brien - New England Journal of Medicine 2014 cited by 1,684

  11. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    Authors: Matthew S. Davids, Andrew W. Roberts, John F. Seymour, John M. Pagel, Brad S. Kahl, William G. Wierda, Soham D. Puvvada, Thomas J. Kipps, Mary Ann Anderson, Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Franklin Peale, Jeremy A. Ross, Lori A. Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod Humerickhouse, Gary Gordon, John F. Gerecitano - Journal of Clinical Oncology 2017 cited by 751

  12. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    Authors: John C. Byrd, Bonnie K. Harrington, Susan O’Brien, Jeffrey A. Jones, Anna Schuh, Steve Devereux, Jorge Chaves, William G. Wierda, Farrukh T. Awan, Jennifer R. Brown, Peter Hillmen, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, John M. Pagel, Jennifer A. Woyach, Dave Johnson, Jane Huang, Xiaolin Wang, Allard Kaptein, Brian J. Lannutti, Todd Covey, Maria Fardis, Jesse McGreivy, Ahmed Hamdy, Wayne Rothbaum, Raquel Izumi, Thomas G. Diacovo, Amy J. Johnson, Richard R. Furman - New England Journal of Medicine 2015 cited by 891

  13. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

    Authors: Brian G. Till, Michael C. Jensen, Jinjuan Wang, Eric Chen, Brent L. Wood, Harvey A. Greisman, Xiaojun Qian, Scott E. James, Andrew Raubitschek, Stephen J. Forman, Ajay K. Gopal, John M. Pagel, Catherine Lindgren, Philip D. Greenberg, Stanley R. Riddell, Oliver W. Press - Blood 2008 cited by 719

  14. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

    Authors: Brian G. Till, Michael C. Jensen, Jinjuan Wang, Xiaojun Qian, Ajay K. Gopal, David G. Maloney, Catherine Lindgren, Yukang Lin, John M. Pagel, Lihua E. Budde, Andrew Raubitschek, Stephen J. Forman, Philip D. Greenberg, Stanley R. Riddell, Oliver W. Press - Blood 2012 cited by 530

  15. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

    Authors: Farrukh T. Awan, Anna Schuh, Jennifer R. Brown, Richard R. Furman, John M. Pagel, Peter Hillmen, Deborah M. Stephens, Jennifer A. Woyach, Елена Бибикова, Prista Charuworn, Melanie M. Frigault, Ahmed Hamdy, Raquel Izumi, Bolan Linghu, Priti Patel, Min Hui Wang, John C. Byrd - Blood Advances 2019 cited by 185

  16. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

    Authors: Jeff P. Sharman, Steven Coutré, Richard R. Furman, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Eugen Tausch, Paula Cramer, Julie Huang, Siddhartha Mitra, Michael Hallek, Susan O’Brien, Stephan Stilgenbauer - Journal of Clinical Oncology 2019 cited by 221

  17. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

    Authors: John C. Byrd, William G. Wierda, Anna Schuh, Stephen Devereux, Jorge Chaves, Jennifer R. Brown, Peter Hillmen, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, John M. Pagel, Jennifer A. Woyach, Kathleen A. Burke, Todd Covey, Michael Gulrajani, Ahmed Hamdy, Raquel Izumi, Melanie M. Frigault, Priti Patel, Wayne Rothbaum, Min Hui Wang, Susan O’Brien, Richard R. Furman - Blood 2019 cited by 178

  18. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

    Authors: Roland B. Walter, Sarah Buckley, John M. Pagel, Brent L. Wood, Barry E. Storer, Brenda M. Sandmaier, Min Fang, Boglarka Gyurkocza, Colleen Delaney, Jerald P. Radich, Elihu H. Estey, Frederick R. Appelbaum - Blood 2013 cited by 357

  19. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

    Authors: John C. Byrd, Peter Hillmen, Susan O’Brien, Jacqueline C. Barrientos, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Patrick Thornton, Carol Moreno, Marco Montillo, John M. Pagel, Jan A. Burger, Jennifer A. Woyach, Sandra Dai, Remus Vezan, Danelle F. James, Jennifer R. Brown - Blood 2019 cited by 243

  20. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

    Authors: Jason R. Westin, Frederick L. Locke, Michael Dickinson, Armin Ghobadi, Mahmoud Elsawy, Tom van Meerten, David B. Miklos, Matthew L. Ulrickson, Miguel‐Angel Perales, Umar Farooq, Luciano Wannesson, Lori A. Leslie, Marie José Kersten, Caron A. Jacobson, John M. Pagel, Gerald Wulf, Patrick B. Johnston, Aaron P. Rapoport, Linqiu Du, Saran Vardhanabhuti, Simone Filosto, Jina Shah, Julia Thornton Snider, Paul Cheng, Christina To, Olalekan O. Oluwole, Anna Sureda - Clinical Cancer Research 2023 cited by 47

  21. Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

    Authors: Roland B. Walter, Ted Gooley, Brent L. Wood, Filippo Milano, Min Fang, Mohamed L. Sorror, Elihu H. Estey, Alexander I. Salter, Emily Lansverk, Jason W. Chien, Ajay K. Gopal, Frederick R. Appelbaum, John M. Pagel - Journal of Clinical Oncology 2011 cited by 399

  22. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

    Authors: Nathan Fowler, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A. Reeves, Wanda Knopińska‐Posłuszny, Chan Y. Cheah, Tycel Phillips, Ewa Lech‐Marańda, Bruce D. Cheson, Paolo F. Caimi, Sebastian Grosicki, Lori A. Leslie, Julio C. Chávez, Gustavo Fonseca, Sunil Babu, Daniel J. Hodson, Spencer H. Shao, John M. Burke, Jeff P. Sharman, Jennie Y. Law, John M. Pagel, Hari P. Miskin, Peter Sportelli, Owen A. O’Connor, Michael Weiss, Pier Luigi Zinzani - Journal of Clinical Oncology 2021 cited by 161

  23. Acalabrutinib in treatment-naive chronic lymphocytic leukemia

    Authors: John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O’Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Stephen Devereux, Peter Hillmen, John M. Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, William G. Wierda - Blood 2021 cited by 98

  24. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

    Authors: Guillermo Garcia‐Manero, Nikolai A. Podoltsev, Megan Othus, John M. Pagel, Jerald P. Radich, Min Fang, David A. Rizzieri, Guido Marcucci, Stephen A. Strickland, Mark R. Litzow, Mary Lynn Savoie, Bruno C. Medeiros, Mikkael A. Sekeres, Tara L. Lin, Geoffrey L. Uy, Bayard L. Powell, Jonathan E. Kolitz, Richard A. Larson, Richard M. Stone, David F. Claxton, James Essell, Selina M. Luger, Sanjay Mohan, Anna Moseley, Frederick R. Appelbaum, Harry P. Erba - Leukemia 2023 cited by 32